{"id":"havrix-720-junior","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site soreness or erythema"},{"rate":"1-5","effect":"Fever"},{"rate":"1-3","effect":"Headache"},{"rate":"1-3","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) hepatitis A virus antigen that triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HAV IgG) and memory B cells, conferring long-term immunity against hepatitis A infection. The 720 junior formulation contains a lower antigen dose (360 ELISA units per 0.5 mL dose) designed for pediatric use.","oneSentence":"Havrix 720 Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:52.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in children aged 1-18 years"}]},"trialDetails":[{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120},{"nctId":"NCT03654664","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-06-20","conditions":"Hepatitis A Vaccine","enrollment":119},{"nctId":"NCT05613127","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs","status":"UNKNOWN","sponsor":"Boryung Biopharma Co., Ltd.","startDate":"2022-12","conditions":"Hepatitis A, Hep A","enrollment":106},{"nctId":"NCT01405677","phase":"PHASE2","title":"Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2004-06","conditions":"Hepatitis A","enrollment":308},{"nctId":"NCT01349829","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-03","conditions":"Hepatitis A","enrollment":251}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Havrix 720 Junior","genericName":"Havrix 720 Junior","companyName":"Chiang Mai University","companyId":"chiang-mai-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Havrix 720 Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in children aged 1-18 years.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}